- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | Aprea Therapeutics reports patent portfolio of 58 patents | - | Investing.com | ||
| 28.08. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.08. | Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs | 174 | GlobeNewswire (Europe) | DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery... ► Artikel lesen | |
| 25.08. | Aprea Therapeutics records second consecutive surge, jumping another 22% | 2 | Seeking Alpha | ||
| 12.08. | Aprea Therapeutics GAAP EPS of -$0.07 beats by $0.16 | 3 | Seeking Alpha | ||
| 12.08. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| APREA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | Aprea Therapeutics Announces Second Quarter 2026 Financial Results | 346 | GlobeNewswire (Europe) | Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma... ► Artikel lesen | |
| 12.08. | Aprea Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 30.07. | Aprea Therapeutics plans Q4 2026 data update for APR-1051 trial | 1 | Investing.com | ||
| 30.07. | Aprea Therapeutics: Daten-Update zur APR-1051-Studie für Q4 2026 geplant | 3 | Investing.com Deutsch | ||
| 23.07. | Aprea Therapeutics, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
| 17.06. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Aprea Therapeutics GAAP EPS of -$0.22 beats by $0.01 | 2 | Seeking Alpha | ||
| 13.05. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | 871 | GlobeNewswire (Europe) | Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the... ► Artikel lesen | |
| 13.05. | Aprea Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 07.05. | This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday | 2 | Benzinga.com | ||
| 07.05. | Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential | 10 | Investing.com | ||
| 21.04. | Aprea Therapeutics abstract accepted at ASCO meeting in May | 1 | Investing.com | ||
| 21.04. | Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,794 | +1,11 % | Evotec-Aktie +5%: Nur ein Strohfeuer oder der Beginn des Rebounds? | Die Kursentwicklung der Evotec-Aktie war zuletzt ein einziges Desaster. Innerhalb der letzten zwölf Monate halbierte sich der Kurs des Wirkstoffforschungsunternehmens und am Dienstag dieser Woche sackte... ► Artikel lesen | |
| BB BIOTECH | 55,10 | -0,72 % | BB Biotech: KI verändert das Wie, nicht das Was | BB Biotech verbindet seit mehr als 30 Jahren wissenschaftliche Expertise mit einem konsequenten Investmentansatz im Biotechnologiesektor. Mit künstlicher Intelligenz entwickelt das Unternehmen diesen... ► Artikel lesen | |
| VALNEVA | 2,869 | +1,24 % | RALLYE bei Valneva: +37,7% Potenzial - Jetzt einsteigen? | ||
| BIOGEN | 193,52 | +3,12 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| ILLUMINA | 209,05 | +0,24 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| CLINUVEL | 5,028 | -1,14 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| BIOCRYST PHARMACEUTICALS | 7,624 | +1,79 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| ABIVAX | 90,45 | -2,89 % | Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | ||
| CARDIOL THERAPEUTICS | 1,662 | +1,84 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| ARBUTUS BIOPHARMA | 4,320 | -0,92 % | Arbutus Biopharma Corp-Aktie im Check am 17.09. (08:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| CARDIFF ONCOLOGY | 1,196 | -0,08 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,036 | +2,48 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| ALDEYRA | 1,180 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 17,405 | +1,34 % | Denali Therapeutics: Markteinführung von Avlayah gewinnt an Fahrt | ||
| ONCO-INNOVATIONS | 0,251 | -5,64 % | Onco-Innovations Ltd: Onco-Innovations issues 860,168 shares for debt |
APREA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,731 Euro und damit -2,68 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APREA THERAPEUTICS INC finden Sie auf Wallstreet Online.